Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 11, 2002

Primary Completion Date

July 20, 2011

Study Completion Date

December 31, 2020

Conditions

Acute Myelogenous LeukemiaMyelodysplastic SyndromeJuvenile Myelomonocytic Leukemia

Interventions

DRUG

Fludarabine

Conditioning Regimen

DRUG

Busulfan

Conditioning Regimen

DRUG

GVHD Prophylaxis

Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)

DRUG

Gemtuzumab Ozogamicin

Dose Escalation

DRUG

Anti-Thymocyte Globulin

Unrelated Donors only

DRUG

Isotretinoin

JMML patients only

Trial Locations (1)

Columbia University Medical Center, New York

All Listed Sponsors

lead

Columbia University

OTHER

NCT01020539 - Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | Biotech Hunter | Biotech Hunter